Opportunistic Infections: Forgotten But Not Gone

Opportunistic Infections: Forgotten But Not Gone

Registration Details

  • Virtual Registration: $35.00 (USD)
  • Virtual Registration ends: Tuesday, September 10, 2024
  • Virtual Fellows: $15.00 (USD)
  • Virtual Fellows ends: Tuesday, September 10, 2024

Chairs

Roger J. Bedimo, MD, MS
University of Texas Southwestern Medical Center
Dallas, TX
Constance A. Benson, MD
University of California San Diego
San Diego, CA

Faculty

Wendy Armstrong, MD
Wendy Armstrong, MD
Emory University
Atlanta, GA
David R. Boulware MD, MPH
University of Minnesota
Minneapolis, MN
Henry Masur, MD
George Washington University
Washington D.C

September 10, 2024

8:00 AM - 1:00 PM PT

Last Modified: Jun 12, 2024 @ 11:28 AM

Program Description

Despite advances in HIV treatment that have reduced the incidence of opportunistic infections (OIs) diseases in people with HIV, there is still a notable number of people who present late to care in the course of HIV infection with preventable and treatable OIs. This virtual course will delve into the most common OIs among people with HIV, which are Pneumocystis jirovecii pneumonia (PJP), cryptococcosis, Mycobacterium avium complex disease (MAC), tuberculosis (TB), Toxoplasma gondii encephalitis, progressive multifocal leukoencephalopathy (PML), and cytomegalovirus (CMV). This course will review the current recommendations of the OI guidelines, clinical and dermatologic manifestation of HIV-related OIs, preventative measures for minimizing disease, and when to initiate antiretroviral therapy in the setting of an acute OI.

Assessment of Needs

According to surveillance reports from the Centers for Disease Control and Prevention (CDC), more than 13% of individuals with HIV are unaware of their infection, and 34% of those aware of their status are not effectively virally suppressed. As a result, OIs continue to cause avoidable illness and death in the US. Health care practitioners involved in HIV care need to stay up to date with the latest advancements in HIV disease management. This virtual course is designed to help practitioners, particularly those new to HIV care and research, understand the implications of new information on strategies for managing OIs in people with HIV.

Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

  • Implement the latest guideline recommendations for treatment, prevention, and management of common HIV-related OIs
  • Recognize when to start antiretroviral therapy in the setting of an acute OI
  • Identify the most common HIV-related OIs
  • Describe the risk factors and common clinical manifestations associated with OIs

Topics

  • Overview of the current Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV
  • Pneumocystis jirovecii pneumonia (PJP)
  • Cryptococcosis
  • Mycobacterium avium complex disease (MAC)
  • Case-based discussion on tuberculosis (TB), Toxoplasma gondii encephalitis, progressive multifocal leukoencephalopathy (PML), cytomegalovirus (CMV), and other OIs

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content. 

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection
  • Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 7 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.

Nursing Credits

This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.